Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jijumon Chelliserry

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of the American Chemical Society|October 11, 2011
Encoding phenotype in bacteria with an alternative genetic setAndrew T Krueger, Larryn W Peterson, Jijumon Chelliserry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast CancerJoanne L Blum, A Douglas Laird, Jennifer K Litton, et al.
The Journal of Molecular Diagnostics : JMD|March 26, 2017
Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher AssayAlba Torres, Mohammed Alshalalfa, Scott A Tomlins, et al.
European Urology|June 2, 2018
The Diverse Genomic Landscape of Clinically Low-risk Prostate CancerMatthew R Cooperberg, Nicholas Erho, June M Chan, et al.
NPJ Breast Cancer|October 6, 2023
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO studyNicholas C Turner, A Douglas Laird, Melinda L Telli, et al.
European Urology Oncology|October 31, 2025
Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to TherapyKarim Fizazi, Johann S de Bono, A Douglas Laird, et al.
European Urology|May 23, 2017
Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy SpecimensPaul L Nguyen, Zaid Haddad, Ashley E Ross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2017
Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate CancerDaniel E Spratt, Jingbin Zhang, María Santiago-Jiménez, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of the American Chemical Society|October 11, 2011
Encoding phenotype in bacteria with an alternative genetic setAndrew T Krueger, Larryn W Peterson, Jijumon Chelliserry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast CancerJoanne L Blum, A Douglas Laird, Jennifer K Litton, et al.
The Journal of Molecular Diagnostics : JMD|March 26, 2017
Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher AssayAlba Torres, Mohammed Alshalalfa, Scott A Tomlins, et al.
European Urology|June 2, 2018
The Diverse Genomic Landscape of Clinically Low-risk Prostate CancerMatthew R Cooperberg, Nicholas Erho, June M Chan, et al.
NPJ Breast Cancer|October 6, 2023
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO studyNicholas C Turner, A Douglas Laird, Melinda L Telli, et al.
European Urology Oncology|October 31, 2025
Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to TherapyKarim Fizazi, Johann S de Bono, A Douglas Laird, et al.
European Urology|May 23, 2017
Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy SpecimensPaul L Nguyen, Zaid Haddad, Ashley E Ross, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2017
Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate CancerDaniel E Spratt, Jingbin Zhang, María Santiago-Jiménez, et al.
Pageof 1